ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation

New York, New York--(Newsfile Corp. - October 1, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ: MLTX) concerning possible violations of federal securities laws.

On September 29, 2025, before the market opened, MoonLake filed with the SEC a current report on Form 8-K. Attached to the current report was a press release which stated that, in MoonLake's VELA-2 trial, "intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy[.]"

On this news, MoonLake stock fell more than 85% on September 29, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=170489&wire=5&utm_campaign=46

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268801